

Bjorn Eliasson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8411321/publications.pdf>

Version: 2024-02-01

112
papers

5,758
citations

66315

42
h-index

82499

72
g-index

112
all docs

112
docs citations

112
times ranked

7405
citing authors

#	ARTICLE	IF	CITATIONS
1	One-Year Treatment With Exenatide Improves β -Cell Function, Compared With Insulin Glargine, in Metformin-Treated Type 2 Diabetic Patients. <i>Diabetes Care</i> , 2009, 32, 762-768.	4.3	354
2	Effects of Exenatide on Measures of β -Cell Function After 3 Years in Metformin-Treated Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2011, 34, 2041-2047.	4.3	221
3	Cigarette smoking and diabetes. <i>Progress in Cardiovascular Diseases</i> , 2003, 45, 405-413.	1.6	220
4	The National Diabetes Register in Sweden: An implementation of the St. Vincent Declaration for Quality Improvement in Diabetes Care. <i>Diabetes Care</i> , 2003, 26, 1270-1276.	4.3	199
5	Risk of cardiovascular disease and mortality in overweight and obese patients with type 2 diabetes: an observational study in 13,087 patients. <i>Diabetologia</i> , 2009, 52, 65-73.	2.9	195
6	Effectiveness and safety of metformin in 51,675 patients with type 2 diabetes and different levels of renal function: a cohort study from the Swedish National Diabetes Register. <i>BMJ Open</i> , 2012, 2, e001076.	0.8	177
7	Cardiovascular disease and mortality in patients with type 2 diabetes after bariatric surgery in Sweden: a nationwide, matched, observational cohort study. <i>Lancet Diabetes and Endocrinology</i> , 2015, 3, 847-854.	5.5	144
8	Risk Prediction of Cardiovascular Disease in Type 2 Diabetes. <i>Diabetes Care</i> , 2008, 31, 2038-2043.	4.3	141
9	Exenatide Affects Circulating Cardiovascular Risk Biomarkers Independently of Changes in Body Composition. <i>Diabetes Care</i> , 2010, 33, 1734-1737.	4.3	139
10	New aspects of HbA1c as a risk factor for cardiovascular diseases in type 2 diabetes: an observational study from the Swedish National Diabetes Register (NDR). <i>Journal of Internal Medicine</i> , 2010, 268, 471-482.	2.7	137
11	Glycemic Control and Cardiovascular Disease in 7,454 Patients With Type 1 Diabetes. <i>Diabetes Care</i> , 2010, 33, 1640-1646.	4.3	122
12	One-year treatment with exenatide vs. Insulin Glargine: Effects on postprandial glycemia, lipid profiles, and oxidative stress. <i>Atherosclerosis</i> , 2010, 212, 223-229.	0.4	118
13	The gap between guidelines and reality: Type 2 diabetes in a national diabetes register 1996-2003. <i>Diabetic Medicine</i> , 2005, 22, 1420-1426.	1.2	114
14	Smoking is associated with increased HbA1c values and microalbuminuria in patients with diabetes—data from the National Diabetes Register in Sweden. <i>Diabetes and Metabolism</i> , 2004, 30, 261-268.	1.4	113
15	Risk factors for the development of albuminuria and renal impairment in type 2 diabetes—the Swedish National Diabetes Register (NDR). <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 1236-1243.	0.4	110
16	Effect of smoking reduction and cessation on cardiovascular risk factors. <i>Nicotine and Tobacco Research</i> , 2001, 3, 249-255.	1.4	102
17	Adipocyte Hypertrophy, Inflammation and Fibrosis Characterize Subcutaneous Adipose Tissue of Healthy, Non-Obese Subjects Predisposed to Type 2 Diabetes. <i>PLoS ONE</i> , 2014, 9, e105262.	1.1	91
18	Diabetes care “improvement through measurement. <i>Diabetes Research and Clinical Practice</i> , 2014, 106, S291-S294.	1.1	90

#	ARTICLE	IF	CITATIONS
19	The Size of Large Adipose Cells Is a Predictor of Insulin Resistance in First-Degree Relatives of Type 2 Diabetic Patients. <i>Obesity</i> , 2012, 20, 932-938.	1.5	89
20	Glycemic and Risk Factor Control in Type 1 Diabetes: Results from 13,612 patients in a national diabetes register. <i>Diabetes Care</i> , 2007, 30, 496-502.	4.3	85
21	Obesity and cardiovascular risk factors in type 2 diabetes: results from the Swedish National Diabetes Register. <i>Journal of Internal Medicine</i> , 2006, 259, 314-322.	2.7	82
22	Exenatide treatment did not affect bone mineral density despite body weight reduction in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2011, 13, 374-377.	2.2	82
23	Recent trends in life expectancy for people with type 1 diabetes in Sweden. <i>Diabetologia</i> , 2016, 59, 1167-1176.	2.9	81
24	Lowering of postprandial lipids in individuals with type 2 diabetes treated with alogliptin and/or pioglitazone: a randomised double-blind placebo-controlled study. <i>Diabetologia</i> , 2012, 55, 915-925.	2.9	80
25	The shape of the metabolic memory of HbA1c: re-analysing the DCCT with respect to time-dependent effects. <i>Diabetologia</i> , 2010, 53, 1093-1098.	2.9	75
26	Albuminuria and renal function as predictors of cardiovascular events and mortality in a general population of patients with type 2 diabetes: A nationwide observational study from the Swedish National Diabetes Register. <i>Diabetes and Vascular Disease Research</i> , 2013, 10, 520-529.	0.9	74
27	Clinical Usefulness of Different Lipid Measures for Prediction of Coronary Heart Disease in Type 2 Diabetes. <i>Diabetes Care</i> , 2011, 34, 2095-2100.	4.3	69
28	A new model for 5-year risk of cardiovascular disease in Type-1 diabetes; from the Swedish National Diabetes Register (NDR). <i>Diabetic Medicine</i> , 2011, 28, 1213-1220.	1.2	67
29	Variability of INR and its relationship with mortality, stroke, bleeding and hospitalisations in patients with atrial fibrillation. <i>Thrombosis Research</i> , 2012, 129, 32-35.	0.8	65
30	Thiazolidinediones increase the wingless-type MMTV integration site family (WNT) inhibitor Dickkopf-1 in adipocytes: a link with osteogenesis. <i>Diabetologia</i> , 2010, 53, 536-540.	2.9	63
31	The True Value of HbA1c as a Predictor of Diabetic Complications: Simulations of HbA1c Variables. <i>PLoS ONE</i> , 2009, 4, e4412.	1.1	61
32	Impact of Socioeconomic Status on Cardiovascular Disease and Mortality in 24,947 Individuals With Type 1 Diabetes. <i>Diabetes Care</i> , 2015, 38, 1518-1527.	4.3	61
33	A new model for 5-year risk of cardiovascular disease in type 2 diabetes, from the Swedish National Diabetes Register (NDR). <i>Diabetes Research and Clinical Practice</i> , 2011, 93, 276-284.	1.1	59
34	Impaired phosphorylation and insulin-stimulated translocation to the plasma membrane of protein kinase B/Akt in adipocytes from Type II diabetic subjects. <i>Diabetologia</i> , 2000, 43, 1107-1115.	2.9	58
35	Long-Term Prognosis in Patients With Type 1 and 2 Diabetes Mellitus After Coronary Artery Bypass Grafting. <i>Journal of the American College of Cardiology</i> , 2015, 65, 1644-1652.	1.2	58
36	Trends in blood pressure control in patients with type 2 diabetes – Data from the Swedish National Diabetes Register (NDR). <i>Blood Pressure</i> , 2011, 20, 348-354.	0.7	57

#	ARTICLE	IF	CITATIONS
37	Microalbuminuria and risk factors in type 1 and type 2 diabetic patients. <i>Diabetes Research and Clinical Practice</i> , 2005, 67, 258-266.	1.1	55
38	Blood pressure and risk of cardiovascular diseases in type 2 diabetes. <i>Journal of Hypertension</i> , 2012, 30, 2020-2030.	0.3	51
39	Hypertension in diabetes: trends in clinical control in repeated large-scale national surveys from Sweden. <i>Journal of Human Hypertension</i> , 2003, 17, 37-44.	1.0	48
40	Weight loss and metabolic effects of topiramate in overweight and obese type 2 diabetic patients: randomized double-blind placebo-controlled trial. <i>International Journal of Obesity</i> , 2007, 31, 1140-1147.	1.6	46
41	Level of physical activity associated with risk of cardiovascular diseases and mortality in patients with type-2 diabetes: report from the Swedish National Diabetes Register. <i>European Journal of Preventive Cardiology</i> , 2014, 21, 244-251.	0.8	45
42	The Impact of Empagliflozin on Obstructive Sleep Apnea and Cardiovascular and Renal Outcomes: An Exploratory Analysis of the EMPA-REG OUTCOME Trial. <i>Diabetes Care</i> , 2020, 43, 3007-3015.	4.3	45
43	Severe Hypoglycemia and Mortality After Cardiovascular Events for Type 1 Diabetic Patients in Sweden. <i>Diabetes Care</i> , 2014, 37, 2974-2981.	4.3	44
44	The triglycerides-to-HDL-cholesterol ratio and cardiovascular disease risk in obese patients with type 2 diabetes: An observational study from the Swedish National Diabetes Register (NDR). <i>Diabetes Research and Clinical Practice</i> , 2014, 106, 136-144.	1.1	44
45	Pulse pressure strongly predicts cardiovascular disease risk in patients with type 2 diabetes from the Swedish National Diabetes Register (NDR). <i>Diabetes and Metabolism</i> , 2009, 35, 439-446.	1.4	41
46	Use of Glucagon-Like Peptide 1 Receptor Agonists and Risk of Serious Renal Events: Scandinavian Cohort Study. <i>Diabetes Care</i> , 2020, 43, 1326-1335.	4.3	41
47	Systolic blood pressure and risk of cardiovascular diseases in type 2 diabetes: an observational study from the Swedish national diabetes register. <i>Journal of Hypertension</i> , 2010, 28, 2026-2035.	0.3	40
48	LDL-cholesterol versus non-HDL-to-HDL-cholesterol ratio and risk for coronary heart disease in type 2 diabetes. <i>European Journal of Preventive Cardiology</i> , 2014, 21, 1420-1428.	0.8	39
49	Glycemic Control in Type 1 Diabetes and Long-Term Risk of Cardiovascular Events or Death After Coronary Artery Bypass Grafting. <i>Journal of the American College of Cardiology</i> , 2015, 66, 535-543.	1.2	39
50	Dust acoustic shock waves. <i>Physical Review E</i> , 2004, 69, 067401.	0.8	37
51	Antihyperglycaemic treatment of type 2 diabetes: results from a national diabetes register. <i>Diabetes and Metabolism</i> , 2007, 33, 269-276.	1.4	37
52	The effect of alogliptin and pioglitazone combination therapy on various aspects of β -cell function in patients with recent-onset type 2 diabetes. <i>European Journal of Endocrinology</i> , 2014, 170, 565-574.	1.9	37
53	Smoking as an independent risk factor for myocardial infarction or stroke in type 2 diabetes: a report from the Swedish National Diabetes Register. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2009, 16, 506-512.	3.1	36
54	HbA1C and Cancer Risk in Patients with Type 2 Diabetes – A Nationwide Population-Based Prospective Cohort Study in Sweden. <i>PLoS ONE</i> , 2012, 7, e38784.	1.1	36

#	ARTICLE	IF	CITATIONS
55	The relationship between the exposure time of insulin glargine and risk of breast and prostate cancer: An observational study of the time-dependent effects of antidiabetic treatments in patients with diabetes. <i>Primary Care Diabetes</i> , 2012, 6, 53-59.	0.9	35
56	Does the choice of EQ-5D tariff matter? A comparison of the Swedish EQ-5D-3L index score with UK, US, Germany and Denmark among type 2 diabetes patients. <i>Health and Quality of Life Outcomes</i> , 2015, 13, 145.	1.0	35
57	Beneficial effects of dalteparin on haemostatic function and local tissue oxygenation in patients with diabetes, severe vascular disease and foot ulcers. <i>Thrombosis Research</i> , 2007, 120, 653-661.	0.8	34
58	Relationship between preoperative hemoglobin A1c levels and long-term mortality after coronary artery bypass grafting in patients with type 2 diabetes mellitus. <i>International Journal of Cardiology</i> , 2016, 202, 291-296.	0.8	33
59	Optimization of basal insulin delivery in Type 1 diabetes: a retrospective study on the use of continuous subcutaneous insulin infusion and insulin glargine. <i>Diabetic Medicine</i> , 2005, 22, 382-386.	1.2	31
60	Effect of tight control of HbA1c and blood pressure on cardiovascular diseases in type 2 diabetes: An observational study from the Swedish National Diabetes Register (NDR). <i>Diabetes Research and Clinical Practice</i> , 2009, 86, 74-81.	1.1	29
61	Impact of ethnicity on progress of glycaemic control in 131 935 newly diagnosed patients with type 2 diabetes: a nationwide observational study from the Swedish National Diabetes Register. <i>BMJ Open</i> , 2015, 5, e007599-e007599.	0.8	29
62	Blood lipids in 75,048 type 2 diabetic patients: a population-based survey from the Swedish National diabetes register. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2011, 18, 97-105.	3.1	28
63	Risk factors for atrial fibrillation in type 2 diabetes: report from the Swedish National Diabetes Register (NDR). <i>Diabetologia</i> , 2015, 58, 2259-2268.	2.9	28
64	Potential Effects of Bariatric Surgery on the Incidence of Heart Failure and Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus and Obesity and on Mortality in Patients With Preexisting Heart Failure: A Nationwide, Matched, Observational Cohort Study. <i>Journal of the American Heart Association</i> , 2021, 10, e019323.	1.6	28
65	Risk factor control in patients with Type 2 diabetes and coronary heart disease: findings from the Swedish National Diabetes Register (NDR). <i>Diabetic Medicine</i> , 2009, 26, 53-60.	1.2	26
66	Clinical Use and Effectiveness of Lipid Lowering Therapies in Diabetes Mellitus—An Observational Study from the Swedish National Diabetes Register. <i>PLoS ONE</i> , 2011, 6, e18744.	1.1	26
67	Population median imputation was noninferior to complex approaches for imputing missing values in cardiovascular prediction models in clinical practice. <i>Journal of Clinical Epidemiology</i> , 2022, 145, 70-80.	2.4	25
68	Glucose-lowering treatment and clinical results in 163 121 patients with type 2 diabetes: an observational study from the Swedish national diabetes register. <i>Diabetes, Obesity and Metabolism</i> , 2012, 14, 717-726.	2.2	24
69	Towards Renewed Health Economic Simulation of Type 2 Diabetes: Risk Equations for First and Second Cardiovascular Events from Swedish Register Data. <i>PLoS ONE</i> , 2013, 8, e62650.	1.1	24
70	LDL cholesterol is not a good marker of cardiovascular risk in Type 1 diabetes. <i>Diabetic Medicine</i> , 2016, 33, 316-323.	1.2	23
71	Adipocyte mitochondrial genes and the forkhead factor FOXC2 are decreased in type 2 diabetes patients and normalized in response to rosiglitazone. <i>Diabetology and Metabolic Syndrome</i> , 2011, 3, 32.	1.2	22
72	Long-term mortality in patients with type 2 diabetes undergoing coronary angiography: the impact of glucose-lowering treatment. <i>Diabetologia</i> , 2012, 55, 2109-2117.	2.9	22

#	ARTICLE	IF	CITATIONS
73	Health Utilities of Type 2 Diabetes-Related Complications: A Cross-Sectional Study in Sweden. <i>International Journal of Environmental Research and Public Health</i> , 2014, 11, 4939-4952.	1.2	22
74	Predicting mortality in people with Type 2 diabetes mellitus after major complications: a study using Swedish National Diabetes Register data. <i>Diabetic Medicine</i> , 2014, 31, 954-962.	1.2	21
75	Costâ€Utility Analysis of Glucagon-Like Peptide-1 Agonists Compared with Dipeptidyl Peptidase-4 Inhibitors or Neutral Protamine Hagedorn Basal Insulin as Add-On to Metformin in Type 2 Diabetes in Sweden. <i>Diabetes Therapy</i> , 2014, 5, 591-607.	1.2	21
76	Additive effects of glycaemia and dyslipidaemia on risk of cardiovascular diseases in type 2 diabetes: an observational study from the Swedish National Diabetes Register. <i>Diabetologia</i> , 2011, 54, 2544-2551.	2.9	19
77	Ongoing treatment with renin-angiotensin-aldosterone-blocking agents does not predict normoalbuminuric renal impairment in a general type 2 diabetes population. <i>Journal of Diabetes and Its Complications</i> , 2013, 27, 229-234.	1.2	19
78	Minor Contribution of Endogenous GLP-1 and GLP-2 to Postprandial Lipemia in Obese Men. <i>PLoS ONE</i> , 2016, 11, e0145890.	1.1	19
79	Aspirin treatment and risk of first incident cardiovascular diseases in patients with type 2 diabetes: an observational study from the Swedish National Diabetes Register. <i>BMJ Open</i> , 2013, 3, e002688.	0.8	18
80	Blood pressure level and risk of major cardiovascular events and all-cause of mortality in patients with type 2 diabetes and renal impairment: an observational study from the Swedish National Diabetes Register. <i>Diabetologia</i> , 2015, 58, 1203-1211.	2.9	18
81	Durability of oral hypoglycemic agents in drug naïve patients with type 2 diabetes: report from the Swedish National Diabetes Register (NDR). <i>BMJ Open Diabetes Research and Care</i> , 2015, 3, e000059.	1.2	17
82	Potential Benefits and Harms of Gastric Bypass Surgery in Obese Individuals With Type 1 Diabetes: A Nationwide, Matched, Observational Cohort Study. <i>Diabetes Care</i> , 2020, 43, 3079-3085.	4.3	17
83	Comparison of Adipose Distribution Indices with Gold Standard Body Composition Assessments in the EMPA-REG H2H SU Trial: A Body Composition Sub-Study. <i>Diabetes Therapy</i> , 2015, 6, 635-642.	1.2	16
84	Type 2 Diabetes, Glycemic Control, and Their Association With Dementia and Its Major Subtypes: Findings From the Swedish National Diabetes Register. <i>Diabetes Care</i> , 2022, 45, 634-641.	4.3	16
85	Amelioration of insulin resistance by rosiglitazone is associated with increased adipose cell size in obese type 2 diabetic patients. <i>Adipocyte</i> , 2014, 3, 314-321.	1.3	15
86	Metabolic Effects of Basal or Premixed Insulin Treatment in 5077 Insulin-Naïve Type 2 Diabetes Patients: Registry-Based Observational Study in Clinical Practice. <i>Diabetes Therapy</i> , 2014, 5, 243-254.	1.2	15
87	A method to predict the metabolic effects of changes in insulin treatment in subgroups of a large population based patient cohort. <i>European Journal of Epidemiology</i> , 2007, 22, 151-157.	2.5	13
88	A Patient-Level Model to Estimate Lifetime Health Outcomes of Patients With Type 1 Diabetes. <i>Diabetes Care</i> , 2020, 43, 1741-1749.	4.3	12
89	Time trends in absolute and modifiable coronary heart disease risk in patients with Type 2 diabetes in the Swedish National Diabetes Register (NDR) 2003â€2008. <i>Diabetic Medicine</i> , 2012, 29, 198-206.	1.2	11
90	Metabolic predictors of impaired glucose tolerance and type 2 diabetes in a predisposed population â€ A prospective cohort study. <i>BMC Endocrine Disorders</i> , 2015, 15, 51.	0.9	11

#	ARTICLE	IF	CITATIONS
91	The role of chloramines in treatment of diabetic foot ulcers: an exploratory multicentre randomised controlled trial. <i>Clinical Diabetes and Endocrinology</i> , 2016, 2, 6.	1.3	11
92	Cephalic phase of insulin secretion in response to a meal is unrelated to family history of type 2 diabetes. <i>PLoS ONE</i> , 2017, 12, e0173654.	1.1	11
93	Predicting Changes in Cardiovascular Risk Factors in Type 2 Diabetes in the Post-UKPDS Era: Longitudinal Analysis of the Swedish National Diabetes Register. <i>Journal of Diabetes Research</i> , 2013, 2013, 1-9.	1.0	10
94	Development of a life expectancy table for individuals with type 1 diabetes. <i>Diabetologia</i> , 2021, 64, 2228-2236.	2.9	10
95	Left-Sided Degenerative Valvular Heart Disease in Type 1 and Type 2 Diabetes. <i>Circulation</i> , 2022, 146, 398-411.	1.6	10
96	The Effect of Insulin Lispro on Glycemic Control in a Large Patient Cohort. <i>Diabetes Technology and Therapeutics</i> , 2009, 11, 51-56.	2.4	9
97	Effect of 3 Years of Treatment With Exenatide on Postprandial Glucagon Levels. <i>Diabetes Care</i> , 2016, 39, e42-e43.	4.3	9
98	Use of incretin-based drugs and risk of cholangiocarcinoma: Scandinavian cohort study. <i>Diabetologia</i> , 2021, 64, 2204-2214.	2.9	9
99	Cardiovascular Disease in Patients with Type 2 Diabetes and in Patients Starting Empagliflozin Treatment: Nationwide Survey. <i>Diabetes Therapy</i> , 2019, 10, 1523-1530.	1.2	8
100	Persistence with IDegLira in Patients in Clinical Practice: A Nationwide Observational Study in Sweden. <i>Diabetes Therapy</i> , 2020, 11, 1807-1820.	1.2	8
101	Glycemic Control and Risk of Sepsis and Subsequent Mortality in Type 2 Diabetes. <i>Diabetes Care</i> , 2022, 45, 127-133.	4.3	7
102	Pathogenesis and treatment of diabetic vascular disease ? illustrated by two cases. <i>Journal of Internal Medicine</i> , 2006, 260, 409-420.	2.7	6
103	Different methods to present the effect of blood pressure on cardiovascular diseases by Cox regression. <i>Journal of Hypertension</i> , 2012, 30, 235-237.	0.3	6
104	Clinical effects, cardiovascular and renal outcomes associated with rapid-acting insulin analogs among individuals with type 2 diabetes: a nation-wide observational cohort study. <i>Clinical Diabetes and Endocrinology</i> , 2017, 3, 5.	1.3	5
105	Long-Term Cost Effectiveness of Oral Semaglutide Versus Empagliflozin and Sitagliptin for the Treatment of Type 2 Diabetes in the Swedish Setting. <i>Pharmacoeconomics - Open</i> , 2022, , 1.	0.9	5
106	Early Clinical Indicators of Addison Disease in Adults With Type 1 Diabetes: A Nationwide, Observational, Cohort Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 1148-1157.	1.8	4
107	Current and future costs of obesity in Sweden. <i>Health Policy</i> , 2022, 126, 558-564.	1.4	4
108	Efficacy and Safety of Treatment with New Basal Insulin Analogues in Type 1 Diabetes: Nation-Wide Survey. <i>Diabetes Therapy</i> , 2020, 11, 725-734.	1.2	3

#	ARTICLE	IF	CITATIONS
109	Sodiumâ€“Glucose Cotransporter 2 Inhibitors and Risk of Bladder and Renal Cancer: Scandinavian Cohort Study. <i>Diabetes Care</i> , 2022, 45, e93-e96.	4.3	3
110	Total costs of basal or premixed insulin treatment in 5077 insulin-naïve type 2 diabetes patients: register-based observational study in clinical practice. <i>Clinical Diabetes and Endocrinology</i> , 2015, 1, 17.	1.3	2
111	Increased Urine IgM and IgG ² Levels, Indicating Decreased Glomerular Size Selectivity, Are Not Affected by Dalteparin Therapy in Patients with Type 2 Diabetes. <i>Biochemistry Research International</i> , 2012, 2012, 1-7.	1.5	1
112	Electrical atrial vulnerability and renal complications in type 2 diabetes. Reply to Montaigne D, Coisne A, Sosner P et al [letter]. <i>Diabetologia</i> , 2016, 59, 863-864.	2.9	1